Comparison of the expression GATA3 in urothelial bladder carcinoma and prostate carcinoma in Hamadan City, West of Iran in 2020

BACKGROUND: Bladder malignancies are a common type of urological cancer leading to a high rate of mortality and morbidity. Bladder cancer is one of the common cancers in the urinary system, which is the 9th cause of cancer in the world. The prompt diagnosis and treatment would result in lower burden of the disease. In this study, immunohistochemical (IHC) assessment of GATA3 expression in bladder carcinoma and prostate carcinoma was assessed . METHODS: In this observational diagnostic study, 90 bladder and 30 prostate cancer biopsies under surgery in Beheshti Hospital in Hamadan City, west of Iran, from February to July 2020, were assessed, and frequency expression of GATA3 in them was evaluated by IHC assay and was compared between bladder carcinoma and prostate carcinoma according to grade. Finally, the results were analyzed by SPSS software. RESULTS: GATA3 was negative in all prostate carcinoma samples, and it was positive in all urothelial bladder carcinoma samples. The higher GATA3 expression was significantly related to the lower grade of bladder tumor (P = 0.001). CONCLUSION: Based on the results obtained, it can be concluded that the expression level of GATA3 in bladder carcinoma reaches 100%.